Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Sponsor's Decision
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
The primary objective of the study is to characterize the persistence to therapy in participants with relapsing forms of multiple sclerosis (RMS) treated with diroximel fumarate (DRF) in routine clinical practice. The secondary objectives of the study are to assess short-term persistence to treatment; to assess long-term persistence on treatment; to assess the effect of DRF on relapses; to assess the impact of DRF on cognition; to assess the impact of DRF on participant reported outcomes (PROs) and to explore the real-world safety profile of DRF (ie, gastrointestinal [GI] tolerability, lymphocyte dynamics, adverse events [AEs] leading to discontinuation, and serious adverse events [SAEs]).
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Label | Type | Description | Intervention Names |
|---|---|---|---|
| Diroximel Fumarate | Participants with RMS who are receiving diroximel fumarate orally in routine clinical practice will be enrolled. |
|
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| Diroximel Fumarate | Drug | As described in the arm. |
|
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of Participants on Treatment with DRF at 1 Year | 1 year |
| Measure | Description | Time Frame |
|---|---|---|
| Percentage of Participants on Treatment with DRF at 3 Months | 3 months | |
| Percentage of Participants on Treatment with DRF at 2 Years | 2 years | |
| Annualized Relapse Rate (ARR) with DRF |
Not provided
Key Inclusion Criteria:
Key Exclusion Criteria:
Note: Other protocol defined Inclusion/Exclusion criteria may apply.
Not provided
Not provided
Not provided
Participants diagnosed with Relapsing forms of multiple sclerosis (RMS) that have been prescribed Diroximel Fumarate under standard clinical care.
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Medical Director | Biogen | Study Director |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Regina Berkovich MD Phd Inc | West Hollywood | California | 90048 | United States | ||
| MedStar Georgetown University Hospital |
In accordance with Biogen's Clinical Trial Transparency and Data Sharing Policy on https://www.biogentrialtransparency.com/
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| At 1 and 2 years |
| Percentage of Participants Relapsed | At 1 and 2 years |
| Change in Processing Speed Test (PST) Score from Baseline | PST measures mental processing speed. The PST will be assessed using multiple sclerosis performance test (MSPT). The participants will be shown some symbols and corresponding numbers. The participants will be then asked to input the numbers corresponding to the given symbols in empty rows. Higher number of correct responses indicates better cognition | Baseline up to 2 years |
| Change in Score for Each Domain of Quality of Life in Neurological Disorders (Neuro- QoL™) Questionnaire | Neuro-QOL uses a T score which has a mean of 50 and SD of 10, based on the norming sample used. All Neuro-QOL banks and scales are scored such that a high score reflects more of what is being measured. | Baseline up to 2 years |
| Change in Disability, as Measured by Patient Determined Disease Steps (PDDS) | The PDDS has nine ordinal levels ranging between 0 (normal) and 8 (bedridden). Higher scores indicate greater disability. | Baseline up to 2 years |
| Change in Work Productivity and Activity Impairment Due to Multiple Sclerosis (WPAI- MS) Scores from Baseline | The Work Productivity and Activity Impairment (WPAI) questionnaire is a validated instrument to measure impairments in work and activities. The WPAI yields four types of scores: 1. Absenteeism (work time missed) 2. Presenteesism (impairment at work / reduced on-the-job effectiveness) 3. Work productivity loss (overall work impairment / absenteeism plus presenteeism) 4. Activity Impairment. Higher numbers indicate greater impairment and less productivity. | Baseline up to 2 years |
| Number of Participants with Gastrointestinal (GI) Adverse Events (AEs) | An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal assessment such as an abnormal laboratory value), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. | Up to 32 months |
| Number of Participants with AEs Leading to Treatment Discontinuation | An AE is any untoward medical occurrence in a participant administered a pharmaceutical product and that does not necessarily have a causal relationship with this treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal assessment such as an abnormal laboratory value), symptom, or disease temporally associated with the use of a medicinal (investigational) product, whether or not related to the medicinal (investigational) product. | Up to 32 months |
| Number of Participants with Serious Adverse Events (SAEs) | An SAE is any untoward medical occurrence that at any dose results in death, in the view of the investigator, places the participant at immediate risk of death, requires inpatient hospitalization or prolongation of existing hospitalization, results in persistent or significant disability/incapacity, results in a congenital anomaly/birth defect or is a medically important event. | Up to 32 months |
| Number of Participants categorized by the types of actions taken to mitigate GI AEs | The actions taken will include temporary dose reduction, temporary dose interruption, initiation of concomitant GI medication, taking DRF dose with food, permanent discontinuation, or other action. | Up to 32 months |
| Median Absolute Lymphocyte Count (ALC) Over Time | Baseline up to 2 years |
| Percent Change in Median ALC from Baseline | Baseline up to 2 years |
| Number of Participants with Lymphopenia According to National Cancer Institute Common Terminology Criteria for Adverse Events (NCI/CTCAE)Severity Grading | Up to 32 months |
| Washington D.C. |
| District of Columbia |
| 20007 |
| United States |
| Norton Neuroscience Institute | Louisville | Kentucky | 40207 | United States |
| Beth Israel Deaconess Medical Center | Boston | Massachusetts | 02215 | United States |
| Glendale Neurological Associates, PC | Farmington | Michigan | 48071 | United States |
| Memorial Healthcare | Owosso | Michigan | 48867 | United States |
| St. Luke's Neurology | Kansas City | Missouri | 64111 | United States |
| CentraState Healthcare System - Linda Cardinale MS Center | Freehold | New Jersey | 07728 | United States |
| MS Center at St Barnabas | Livingston | New Jersey | 07039 | United States |
| Multiple Sclerosis Center JSUMC | Neptune City | New Jersey | 07753 | United States |
| Jacobs School of Medicine and Biomedical Sciences | Buffalo | New York | 14202 | United States |
| Cone Health | Greensboro | North Carolina | 27405 | United States |
| Providence Brain and Spine Institute | Portland | Oregon | 97225 | United States |
| Geisinger Medical Center | Danville | Pennsylvania | 17822 | United States |
| Hope Neurology | Knoxville | Tennessee | 37922 | United States |
| UTHealth Neurosciences Texas Medical Center II | Houston | Texas | 77030 | United States |
| Riverside Neurology Specialists | Newport News | Virginia | 23601 | United States |
| Providence Medical Research Center | Spokane | Washington | 99204 | United States |
| ID | Term |
|---|---|
| D009103 | Multiple Sclerosis |
| ID | Term |
|---|---|
| D020278 | Demyelinating Autoimmune Diseases, CNS |
| D020274 | Autoimmune Diseases of the Nervous System |
| D009422 | Nervous System Diseases |
| D003711 | Demyelinating Diseases |
| D001327 | Autoimmune Diseases |
| D007154 | Immune System Diseases |
Not provided
Not provided
| ID | Term |
|---|---|
| C000722501 | diroximel fumarate |
Not provided
Not provided
Not provided